• Product NameAT7519
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityAT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 2.
• Target NameCDK inhibitor; GSK-3 inhibitor
• CAS No. 844442-38-2
• Calculated MW 382.24
• Formulation C16H17Cl2N5O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 |c:3,6,15,t:1,12|
  Pathways:PI3K/Akt/mTOR signaling; Cell Cycle/Checkpoint; Stem Cells
  Receptor:CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3β
  Boling pt:
  Melting pt:
  Solubility:DMSO:10 mg/mL (26.16 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Squires MS, et al. Mol Cancer Ther, 2009, 8(2), 324-332.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting